However, a Phase 2b trial with this drug candidate very recently failed to reach the primary outcome measure of ACR20 after 12 weeks in RA patients with inadequate responses to either anti-TNFα (NCT01636817) or methotrexate (NCT01636843) therapy. The gene discussed is TNF; the disease is rheumatoid arthritis.